<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Onco Targets Ther</journal-id><journal-id journal-id-type="iso-abbrev">Onco Targets Ther</journal-id><journal-id journal-id-type="publisher-id">OncoTargets and Therapy</journal-id><journal-title-group><journal-title>OncoTargets and therapy</journal-title></journal-title-group><issn pub-type="epub">1178-6930</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4712971</article-id><article-id pub-id-type="doi">10.2147/OTT.S91748</article-id><article-id pub-id-type="publisher-id">ott-9-191</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Bioinformatics analysis of hepatitis C virus genotype 2a-induced human hepatocellular carcinoma in Huh7 cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Ping</given-names></name><xref ref-type="aff" rid="af1-ott-9-191">1</xref><xref ref-type="aff" rid="af2-ott-9-191">2</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Meiying</given-names></name><xref ref-type="aff" rid="af2-ott-9-191">2</xref><xref ref-type="aff" rid="af3-ott-9-191">3</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="af1-ott-9-191">1</xref><xref ref-type="aff" rid="af2-ott-9-191">2</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Junchi</given-names></name><xref ref-type="aff" rid="af1-ott-9-191">1</xref><xref ref-type="aff" rid="af2-ott-9-191">2</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Minjuan</given-names></name><xref ref-type="aff" rid="af1-ott-9-191">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ming</given-names></name><xref ref-type="aff" rid="af4-ott-9-191">4</xref></contrib><contrib contrib-type="author"><name><surname>Qian</surname><given-names>Feng</given-names></name><xref ref-type="aff" rid="af4-ott-9-191">4</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Junhua</given-names></name><xref ref-type="aff" rid="af2-ott-9-191">2</xref><xref ref-type="aff" rid="af4-ott-9-191">4</xref><xref ref-type="corresp" rid="c1-ott-9-191"/></contrib></contrib-group><aff id="af1-ott-9-191"><label>1</label>Inspection Center, Affiliated Infectious Hospital of Soochow University, Suzhou, Jiangsu Province, People&#x02019;s Republic of China</aff><aff id="af2-ott-9-191"><label>2</label>Key Laboratory of TB Prevention and Cure of Suzhou City, Suzhou, Jiangsu Province, People&#x02019;s Republic of China</aff><aff id="af3-ott-9-191"><label>3</label>Department of Respiratory Medicine, Affiliated Infectious Hospital of Soochow University, Suzhou, Jiangsu Province, People&#x02019;s Republic of China</aff><aff id="af4-ott-9-191"><label>4</label>Department of Infectious Diseases, Affiliated Infectious Hospital of Soochow University, Suzhou, Jiangsu Province, People&#x02019;s Republic of China</aff><author-notes><corresp id="c1-ott-9-191">Correspondence: Junhua Xu, Inspection Center, The Affiliated Infectious Hospital of Soochow University, No 1 Xi&#x02019;er Road, Gusu District, Suzhou 215007, Jiangsu Province, People&#x02019;s Republic of China, Tel/fax +86 512 6518 8088, Email <email>junhuaxuu@163.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>08</day><month>1</month><year>2016</year></pub-date><volume>9</volume><fpage>191</fpage><lpage>202</lpage><permissions><copyright-statement>&#x000a9; 2016 Xu et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2016</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><p>Hepatocellular carcinoma (HCC) is a liver cancer that could be induced by hepatitis C virus genotype 2a Japanese fulminant hepatitis-1 (JFH-1) strain. The aim of this study was to investigate the molecular mechanisms of HCC. The microarray data GSE20948 includes 14 JFH-1- and 14 mock (equal volume of medium [control])-infected Huh7 samples. The data were downloaded from the Gene Expression Omnibus. After data processing, soft cluster analyses were performed to identify co-regulated genes with similar temporal expression patterns. Functional and pathway enrichment analyses, as well as functional annotation analysis, were performed. Subsequently, combined networks of protein&#x02013;protein interaction network, microRNA regulatory network, and transcriptional regulatory network were constructed. Hub nodes, modules, and five clusters of co-regulated genes were also identified. In total, 173 up and 207 down co-regulated genes were separately identified in JFH-1-infected Huh7 cells compared with those of control cells. Functional enrichment analysis indicated that up co-regulated genes were related to skeletal system morphogenesis and neuron differentiation and down co-regulated genes were related to steroid/cholesterol/sterol metabolisms. Hub genes (such as <italic>IRF1</italic>, <italic>GBP1</italic>, <italic>ICAM1</italic>, <italic>Foxa1</italic>, <italic>DHCR7</italic>, <italic>HMGCS2</italic>, and <italic>MSMO1</italic>) were identified. Transcription factors <italic>IRF1</italic> and <italic>Foxa1</italic> were the targets of miR-130a, miR-17-5p, and miR-20a. <italic>PPARGC1A</italic> was targeted by miR-29 family, and <italic>MSMO1</italic> was the target of miR-23 family. Hub nodes (such as <italic>IRF1</italic>, <italic>GBP1</italic>, <italic>ICAM1</italic>, <italic>Foxa1</italic>, <italic>DHCR7</italic>, <italic>HMGCS2</italic>, and <italic>MSMO1</italic>) and microRNAs might be used as candidate biomarkers of JFH-1-infected HCC.</p></abstract><kwd-group><title>Keywords</title><kwd>soft cluster analysis</kwd><kwd>co-regulated genes</kwd><kwd>transcription factors</kwd><kwd>microRNAs</kwd><kwd>combined network</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Hepatocellular carcinoma (HCC) is the seventh most common cancer in women, the fifth most common cancer in men, and the third leading cause of cancer death.<xref rid="b1-ott-9-191" ref-type="bibr">1</xref> Hepatitis C virus (HCV) is a common blood-borne viral infection resource and a leading cause of chronic liver diseases including HCC.<xref rid="b2-ott-9-191" ref-type="bibr">2</xref> Persistent viremia induced by HCV infection is believed to be the main cause of sustained liver dysfunction and higher HCC rate.<xref rid="b3-ott-9-191" ref-type="bibr">3</xref> Indi viduals with substantial or repeated direct percutaneous exposures such as injecting drugs, receiving blood from infected donors, hemophilia, and surgical resection have a higher prevalence of antibody to HCV.<xref rid="b2-ott-9-191" ref-type="bibr">2</xref>,<xref rid="b4-ott-9-191" ref-type="bibr">4</xref> In North American and Western European countries, antibody to HCV has been detected in the serum of nearly 70% of HCC patients.<xref rid="b5-ott-9-191" ref-type="bibr">5</xref>,<xref rid="b6-ott-9-191" ref-type="bibr">6</xref></p><p>In recent years, investigations on HCC mechanisms have been extensively performed. Studies have shown that genetic factors, metabolic factors, and environment conditions were the main causes of HCC.<xref rid="b2-ott-9-191" ref-type="bibr">2</xref>,<xref rid="b4-ott-9-191" ref-type="bibr">4</xref> After being infected with HCV, patients frequently develop liver steatosis pathophysiology<xref rid="b7-ott-9-191" ref-type="bibr">7</xref> and show resistance to interferon (IFN) treatment.<xref rid="b8-ott-9-191" ref-type="bibr">8</xref>,<xref rid="b9-ott-9-191" ref-type="bibr">9</xref> HCV is a lipotropic virus associated with serum lipoprotein.<xref rid="b10-ott-9-191" ref-type="bibr">10</xref> The replication and infectivity of HCV can be regulated by cellular lipid status,<xref rid="b4-ott-9-191" ref-type="bibr">4</xref> making serum lipoprotein level a good candidate marker and therapy for HCV-induced disease progression.<xref rid="b11-ott-9-191" ref-type="bibr">11</xref></p><p>Gene expression profile analyses have revealed that the genes associated with lipid metabolism and viral particle production can be repressed by microRNAs (miRNAs).<xref rid="b10-ott-9-191" ref-type="bibr">10</xref> Shirasaki et al revealed that overexpression of miR-27a decreases viral infectivity, enhances IFN signaling, and develops a more favorable response to IFN therapy.<xref rid="b10-ott-9-191" ref-type="bibr">10</xref> Previous studies focusing on miRNAs suggest the regulatory effect of miRNAs such as miR-130a,<xref rid="b12-ott-9-191" ref-type="bibr">12</xref> miR-196,<xref rid="b13-ott-9-191" ref-type="bibr">13</xref> and Let-7b<xref rid="b14-ott-9-191" ref-type="bibr">14</xref> on lipid metabolism and HCV replication, indicating that miRNAs have therapeutic potential for HCV-induced HCC patients. In addition, downregulation of HCC-related protein 1 may be related to decrease the invasion of HCC cells.<xref rid="b15-ott-9-191" ref-type="bibr">15</xref>
<italic>HCCA1</italic> plays an active role in HCC carcinogenesis and progression, and it may be used as a marker for HCC diagnosis and a potential target for treatment of this disease.<xref rid="b16-ott-9-191" ref-type="bibr">16</xref></p><p>As a genotype 2a HCV clone, HCV genotype 2a Japanese fulminant hepatitis-1 (JFH-1) strain can undergo a complete infection cycle in cell culture. This makes it possible to clarify the influence of HCV infection on host gene expression.<xref rid="b13-ott-9-191" ref-type="bibr">13</xref>,<xref rid="b17-ott-9-191" ref-type="bibr">17</xref> In 2010, Blackham et al<xref rid="b18-ott-9-191" ref-type="bibr">18</xref> used microarray data to analyze the differentially expressed genes (DEGs) between JFH-1-infected Huh7 cell samples and mock-infected Huh7 cell samples (controls). They demonstrated that JFH-1 infection decreased the expression of genes involved in lipid metabolism (<italic>TXNIP</italic> and <italic>CYP1A1</italic>) and increased the expression of genes involved in cellular defense metabolism (<italic>CXCR1</italic> and <italic>CXCR2</italic>). However, they did not perform the regulatory analysis of transcriptional and miRNA regulatory interrelationships. Thus, the miRNA regulation of these genes still remains unclear.</p><p>Using the microarray data GSE20948 released by Blackham et al,<xref rid="b18-ott-9-191" ref-type="bibr">18</xref> we first identified the co-regulated genes with similar temporal expression patterns. Then, the miRNAs related to the co-regulated genes were predicted to construct the regulatory network. Gene ontology (GO) and pathway analysis showed that the up co-regulated genes induced by JFH-1 infection were associated with neuron differentiation, response to virus, and immune response, and the down co-regulated genes were significantly relevant to steroid and cholesterol metabolic processes. Moreover, the genes and miRNAs were validated in HCC samples downloaded from The Cancer Genome Atlas (TCGA). This study indicated the importance of genes and miRNAs in HCC induced by HCV infection and the potential therapeutic properties of those miRNAs and genes for HCV-infected HCC.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec sec-type="methods"><title>Microarray data</title><p>Expression profile of GSE20948 released by Blackham et al<xref rid="b18-ott-9-191" ref-type="bibr">18</xref> was downloaded from the Gene Expression Omnibus (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</ext-link>) based on the platform of GPL570 (HG-U133_Plus_2) Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA, USA). GSE20948 includes 14 JFH-1-infected Huh7 cell samples and 14 mock-infected Huh7 cell samples, taken at 6 hours, 12 hours, 18 hours, 24 hours, and 48 hours post treatment (three repeats for each time point, the first repeat of both JFH-1- and mock-infected Huh7 cell samples at 6 hours post infection/treatment was not enrolled due to its poor quality).<xref rid="b18-ott-9-191" ref-type="bibr">18</xref></p></sec><sec sec-type="methods"><title>Data processing</title><p>After downloading GSE20948, microarray data were preprocessed by the Affy package (<ext-link ext-link-type="uri" xlink:href="http://www.bioconductor.org">http://www.bioconductor.org</ext-link>).<xref rid="b19-ott-9-191" ref-type="bibr">19</xref> Probe identity documents of the raw data were converted to gene symbols using robust multi-array analysis package<xref rid="b20-ott-9-191" ref-type="bibr">20</xref> in Bioconductor (<ext-link ext-link-type="uri" xlink:href="http://www.bioconductor.org/">http://www.bioconductor.org/</ext-link>). For each transcript, mean expression values for each gene were determined by averaging the individual expression values. Then, the average expression values of transcripts in JFH-1-infected samples were normalized against those in mock-infected samples at the corresponding time points, which were considered as the fold changes. Subsequently, the log 2 transformation was performed. Finally, gene expression matrix of the samples was obtained.</p></sec><sec sec-type="methods"><title>Soft cluster analysis and identification of co-regulated genes</title><p>Soft cluster analysis was performed to detect the groups of transcripts with similar expression pattern during the experimental period. The Mfuzz package<xref rid="b21-ott-9-191" ref-type="bibr">21</xref> was used to conduct noise-robust soft cluster analysis to obtain the co-regulated genes with a similar expression pattern at five time points. The cluster algorithm was the fuzzy c-means algorithm.<xref rid="b22-ott-9-191" ref-type="bibr">22</xref> The parameters of minimum standard deviation and score were set as 0.1 and 0.6, respectively. A degree of membership of gene &#x0003e;0.6 was used as the inclusion criterion of co-regulated genes with a similar expression pattern.</p></sec><sec sec-type="methods"><title>Functional and pathway enrichment analysis for genes in modules</title><p>The Database for Annotation, Visualization, and Integrated Discovery<xref rid="b23-ott-9-191" ref-type="bibr">23</xref> was used to identify the significant GO biological process categories and the Kyoto Encyclopedia of Genes and Genomes pathway terms related to co-regulated genes. <italic>P</italic>&#x0003c;0.05 and enriched gene count &#x0003e;2 were used as the cutoff criteria.</p></sec><sec><title>Screening of transcription factors, oncogenes, and tumor suppressor genes</title><p>To determine whether the genes in clusters had functions of transcription factors (TFs), TF database (<ext-link ext-link-type="ftp" xlink:href="ftp://ftp.ncbi.nlm.nih.gov/repository/TFD/datasets/">ftp://ftp.ncbi.nlm.nih.gov/repository/TFD/datasets/</ext-link>)<xref rid="b24-ott-9-191" ref-type="bibr">24</xref> was used to screen TFs among the co-regulated genes. In addition, by combining with tumor-associated genes (TAGs) database (<ext-link ext-link-type="uri" xlink:href="http://www.binfo.ncku.edu.tw/TAG/">http://www.binfo.ncku.edu.tw/TAG/</ext-link>)<xref rid="b25-ott-9-191" ref-type="bibr">25</xref> and tumor suppressor genes (TSGs) database (<ext-link ext-link-type="uri" xlink:href="http://bioinfo.mc.vanderbilt.edu/TSGene/">http://bioinfo.mc.vanderbilt.edu/TSGene/</ext-link>),<xref rid="b26-ott-9-191" ref-type="bibr">26</xref> all known oncogenes and TSGs were further extracted from the co-regulated genes.</p></sec><sec sec-type="methods"><title>Protein&#x02013;protein interaction network analysis</title><p>The STRING online software (<ext-link ext-link-type="uri" xlink:href="http://string-db.org/">http://string-db.org/</ext-link>)<xref rid="b27-ott-9-191" ref-type="bibr">27</xref> was used to determine the protein&#x02013;protein interaction (PPI) relationships of all the genes with confidence (combined score) &#x0003e;0.4. The other parameters were set to the defaults.</p></sec><sec><title>miRNA prediction</title><p>The WebGestalt tool (<ext-link ext-link-type="uri" xlink:href="http://bioinfo.vanderbilt.edu/webgestalt/">http://bioinfo.vanderbilt.edu/webgestalt/</ext-link>)<xref rid="b28-ott-9-191" ref-type="bibr">28</xref> was used to predict miRNAs (enriched gene count &#x02265;2 and raw <italic>R</italic>&#x0003c;0.05) targeting the tightly co-regulated genes by using the cumulative hypergeometric distribution. Then, the raw <italic>P</italic>-values were adjusted to false discovery rates (FDRs) using the Benjamini and Hochberg method in a multi-test package.<xref rid="b29-ott-9-191" ref-type="bibr">29</xref> The FDR &#x0003c;0.05 was taken as the threshold.</p></sec><sec><title>Screening of transcriptional regulatory interrelationships</title><p>Based on the TF regulatory network data in the Encyclopedia of DNA Elements (ENCODE, <ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu/ENCODE">http://genome.ucsc.edu/ENCODE</ext-link>),<xref rid="b30-ott-9-191" ref-type="bibr">30</xref> transcriptional interrelationships were identified.</p></sec><sec><title>Combination of networks</title><p>The combination of the PPI network, miRNA regulatory network, and transcriptional regulatory network was performed using the Cytoscape software (<ext-link ext-link-type="uri" xlink:href="http://www.cytoscape.org/">http://www.cytoscape.org/</ext-link>).<xref rid="b31-ott-9-191" ref-type="bibr">31</xref> Then, the key nodes (hub proteins) in the PPI network were identified using connectivity degree analysis.<xref rid="b32-ott-9-191" ref-type="bibr">32</xref></p></sec><sec sec-type="methods"><title>Module analysis</title><p>The Molecular Complex Detection (MCODE, <ext-link ext-link-type="uri" xlink:href="http://baderlab.org/Software/MCODE">http://baderlab.org/Software/MCODE</ext-link>)<xref rid="b33-ott-9-191" ref-type="bibr">33</xref> was used to screen the modules of PPI network (degree cutoff, 2; node score cutoff, 0.2; K-core, 2; maximum depth, 100). The MCODE score &#x0003e;3 and number of nodes &#x0003e;4 were used as the cutoff criteria. Afterward, functional and pathway enrichment analyses were performed for the co-regulated genes in the modules. <italic>P</italic>&#x0003c;0.05 and enriched gene count &#x0003e;2 were used as the cutoff criteria.</p></sec><sec><title>Validation of the key genes and miRNAs</title><p>The level 3 data of miRNASeq (including 372 HCC samples and 50 control samples) and RNASeq V2 (including 371 HCC samples and 50 control samples) were downloaded from TCGA (<ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>). The raw counts in miRNA or gene levels were selected from the data, and the miRNAs or genes, which had not been found in &#x0003e;20% of samples, were rejected. Then, the expression matrix was normalized by trimmed mean of M values method.<xref rid="b34-ott-9-191" ref-type="bibr">34</xref> The differentially expressed miRNAs (DE-miRNAs) and DEGs were identified by edgeR package<xref rid="b35-ott-9-191" ref-type="bibr">35</xref> in R. The FDR &#x0003c;0.01 and |log fold change| &#x02265;1 were used as the cutoff criteria.</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="methods"><title>Soft cluster analysis</title><p>Using the Mfuzz software, we obtained five clusters of temporal expression patterns (<xref ref-type="fig" rid="f1-ott-9-191">Figure 1</xref>). Genes in clusters 1 and 4 showed the increasing expression patterns, whereas genes in clusters 2 and 3 showed the decreasing expression ratios along with the extension of time. The temporal expression patterns of genes in clusters 1 and 2 were basically opposite to those in clusters 3 and 4, respectively. The genes in cluster 5 did not have unified expression profiles and did not have opposite time-dependent patterns. Thus, we performed further analysis for the co-regulated genes in clusters 1&#x02013;4.</p><p>Accordingly, a total of 380 genes including 173 co-regulated genes with continuously increasing temporal expression patterns (up co-regulated genes, 93 genes in cluster 1 and 80 genes in cluster 4) and 207 co-regulated genes with continuously decreasing temporal expression patterns (down co-regulated genes, 112 genes in cluster 2 and 95 genes in cluster 3) were identified.</p></sec><sec><title>Functional and pathway enrichment analyses</title><p>We separately performed the GO enrichment analysis for the up and down co-regulated genes. The up co-regulated genes were associated with response to skeletal system morphogenesis (<italic>P</italic>=3.67E-0<sub>3</sub>) and neuron differentiation (<italic>P</italic>=6.99E-0<sub>3</sub>; <xref ref-type="table" rid="t1-ott-9-191">Table 1</xref>). The down co-regulated genes were significantly relevant to steroid metabolic process (<italic>P</italic>=1.21E-06) and cholesterol metabolic process (<italic>P</italic>=4.61E-05). Pathway enrichment analysis showed that the up co-regulated genes were associated with starch and sucrose metabolism pathway (<italic>P</italic>=5.48E-02; <xref ref-type="table" rid="t2-ott-9-191">Table 2</xref>) and the down co-regulated genes were related to intestinal immune network for immunoglobulin A production pathway (<italic>P</italic>=2.05E-02; <xref ref-type="table" rid="t2-ott-9-191">Table 2</xref>).</p></sec><sec><title>Screening of TFs, oncogenes, and TSGs</title><p>Using the TF, TAG, and TSG database, we obtained 12 TFs (eg, <italic>BACH2</italic>, IFN-&#x003b3; regulatory factor-1 (<italic>IRF1</italic>), <italic>Hoxa2</italic>, <italic>Hoxb7</italic>, and <italic>MAFK</italic>) and eleven TSGs (eg, <italic>BACH2</italic>, <italic>IRF1</italic>, and <italic>TRIM3</italic>) from the up co-regulated genes, as well as ten TFs (eg, <italic>Foxa1</italic>, <italic>CDX2</italic>, and <italic>SMAD6</italic>), seven TSGs (eg, <italic>CDKN2C</italic> and <italic>DKK1</italic>), and two oncogenes (<italic>ETV1</italic> and <italic>GPX2</italic>) from the down co-regulated genes (<xref ref-type="table" rid="t3-ott-9-191">Table 3</xref>).</p></sec><sec sec-type="methods"><title>PPI network analysis</title><p>We analyzed the interrelationship of all the up and down co-regulated genes. The PPI network of the up co-regulated genes was composed of 39 nodes (products of genes) and 77 edges (interrelationships), such as IRF1 (degree =25), MAFK (degree =13), intercellular adhesion molecule-1 (ICAM1; degree =7), and IRF9 (degree =7; <xref ref-type="table" rid="t4-ott-9-191">Table 4</xref>). The PPI network of the down co-regulated genes was composed of 53 nodes and 90 edges, such as Foxa1 (degree =49), CDX2 (degree =10), methylsterol monooxygenase 1 (MSMO1; degree =8), hydroxymethylglutaryl CoA synthase 2 (HMGCS2; degree =7), delta7-sterol reductase (DHCR7; degree =7), and mevalonate diphosphate decarboxylase (MVD; degree =6; <xref ref-type="table" rid="t4-ott-9-191">Table 4</xref>).</p></sec><sec><title>Combination of the networks</title><p>Using the WebGestalt online tool, we predicted the miRNAs that might regulate the co-regulated genes in the PPI networks. Then, we further identified the transcriptional regulatory network using ENCODE. Finally, the combined networks of the PPI network, miRNA regulatory network, and transcriptional regulatory network of the up and down co-regulated genes were constructed and visualized using Cytoscape software, respectively (<xref ref-type="fig" rid="f2-ott-9-191">Figure 2</xref>). Hub nodes in each network were identified. <xref ref-type="fig" rid="f3-ott-9-191">Figure 3</xref> shows the combined networks with the hub nodes of <italic>IRF1</italic> (<xref ref-type="fig" rid="f3-ott-9-191">Figure 3A</xref>) and <italic>Foxa1</italic> (<xref ref-type="fig" rid="f3-ott-9-191">Figure 3B</xref>).</p><p>Interrelationships such as ICAM1&#x02013;IRF1 (score =0.990) and IRF9&#x02013;IRF1 (score =0.979) were identified in the network of the up co-regulated genes. Genes such as <italic>IRF1</italic> and <italic>TRIM3</italic> were the targets of miR-130a, miR-301, miR-181b, miR-17-5p, miR-20a, miR-106a, and so on. <italic>PPARGC1A</italic> was targeted by miR-29a, miR-29b, miR-29c, and so on (<xref ref-type="fig" rid="f2-ott-9-191">Figure 2A</xref>). Moreover, transcriptional regulatory interrelationships of <italic>IRF1</italic> with other ten genes such as <italic>MX1</italic>, <italic>IRF9</italic>, and <italic>ICAM1</italic> were identified (<xref ref-type="fig" rid="f2-ott-9-191">Figures 2A</xref> and <xref ref-type="fig" rid="f3-ott-9-191">3A</xref>).</p><p>In the combined network of the down co-regulated genes, interrelationships such as MSMO1&#x02013;farnesyl-diphosphate farnesyltransferase 1 (FDFT1; score =0.993), HMGCS2&#x02013;MVD (score =0.940), and DHCR7&#x02013;MSMO1 (score =0.868) were obtained. The <italic>Foxa1</italic> gene was the target of miR-20a, miR-17-5p, miR-106a, miR-519d, and so on, and <italic>MSMO1</italic> was targeted by miR-23a, miR-23b, and so on (<xref ref-type="fig" rid="f2-ott-9-191">Figure 2B</xref>). In addition, transcriptional regulatory interrelationships of <italic>Foxa1</italic> with 42 other genes including <italic>HMGCS2</italic> and <italic>PGM2L1</italic> were identified (<xref ref-type="fig" rid="f2-ott-9-191">Figures 2B</xref> and <xref ref-type="fig" rid="f3-ott-9-191">3B</xref>).</p></sec><sec sec-type="methods"><title>Module analysis</title><p><xref ref-type="fig" rid="f4-ott-9-191">Figure 4</xref> shows the most significant modules of networks for the up (mode score =6.333; <xref ref-type="fig" rid="f4-ott-9-191">Figure 4A</xref>) and down co-regulated genes (mode score =4.8; <xref ref-type="fig" rid="f4-ott-9-191">Figure 4B</xref>). The module of PPI network of up co-regulated genes consisted of seven nodes and 19 edges (<xref ref-type="fig" rid="f4-ott-9-191">Figure 4A</xref>). Enrichment analysis showed that these genes were mainly associated with immune response (<italic>P</italic>=3.40E-02) and response to virus (<italic>P</italic>=4.74E-02; <xref ref-type="table" rid="t5-ott-9-191">Table 5</xref>). There were no enriched pathways for these genes.</p><p>The module of PPI network of down co-regulated genes contained six nodes and 12 edges (<xref ref-type="fig" rid="f4-ott-9-191">Figure 4B</xref>). GO enrichment analysis revealed that the genes were enriched in cholesterol metabolic process (<italic>P</italic>=1.21E-06), sterol metabolic process (<italic>P</italic>=1.61E-06), isoprenoid metabolic process (<italic>P</italic>=1.29E-02), and lung development (<italic>P</italic>=2.90E-02; <xref ref-type="table" rid="t5-ott-9-191">Table 5</xref>). Down co-regulated genes of HMGCS2 and MVD were involved in terpenoid backbone biosynthesis pathway (<italic>P</italic>=8.83E-03).</p></sec><sec><title>Validation of the key genes and miRNAs</title><p>A total of 113 DE-miRNAs (including 97 upregulated and 16 downregulated miRNAs, such as miR-17 and miR-20a) and 3,069 DEGs (including 2,103 upregulated and 966 downregulated genes, such as <italic>GBP1</italic> and <italic>HMGCS2</italic>) were screened. Afterward, the DEGs were compared with the co-regulated genes in clusters 1&#x02013;4. A total of 11, 21, 14 (eg, <italic>HMGCS2</italic>), and 19 (eg, <italic>GBP2</italic>) DEGs were found in clusters 1, 2, 3, and 4, respectively.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p><italic>IRF1</italic> gene is a TF that regulates the transcription of type I IFN- and IFN-inducible genes.<xref rid="b36-ott-9-191" ref-type="bibr">36</xref> As an antiviral pleiotropic cytokine,<xref rid="b37-ott-9-191" ref-type="bibr">37</xref> IFN-&#x003b3; can result in non-apoptotic cell death of Huh7 cells or human HCC cells by inducing autophagosome formation and autophagy in cells via IRF1 signaling pathway.<xref rid="b38-ott-9-191" ref-type="bibr">38</xref> A previous study suggested that the &#x02212;300AA IRF1 genotype may be related to the outcome in HCV genotype 3-infected patients and therapeutic response in patients infected by HCV genotype 1.<xref rid="b39-ott-9-191" ref-type="bibr">39</xref> Thus, <italic>IRF1</italic> was associated with the prognosis of HCC patients.</p><p>miR-17-5p is the most determinant regulator of the G1/S phase cell cycle transition.<xref rid="b40-ott-9-191" ref-type="bibr">40</xref> HEK293T cells transiently transfected with miR-17-5p develop a dramatic increment in the proliferation rate.<xref rid="b40-ott-9-191" ref-type="bibr">40</xref> However, the <italic>IRF1</italic> mRNA expression levels increase and the proliferation rate of HEK293T cells reduces subsequently. This might be due to the autophagy triggered by <italic>IRF1</italic>. These results indicate that <italic>IRF1</italic> can reduce the hypo-proliferation phenotype of tumor cells.<xref rid="b40-ott-9-191" ref-type="bibr">40</xref>,<xref rid="b41-ott-9-191" ref-type="bibr">41</xref> In this study, we predicted that <italic>IRF1</italic> was targeted by miRNAs of miR-130a, miR-301, miR-181b, miR-17-5p, miR-20a, miR-106a, and so on, indicating the vital role of <italic>IRF1</italic> in regulating proliferation of HCC cells.</p><p>Both <italic>GBP1</italic> and <italic>GBP2</italic> expressions require TF <italic>IRF1</italic> activation.<xref rid="b42-ott-9-191" ref-type="bibr">42</xref> Like <italic>IRF1</italic>, immunostaining indicates that GBP1/2 accumulation in intracellular compartments contributes to cell autophagy,<xref rid="b43-ott-9-191" ref-type="bibr">43</xref> which inhibits the growth of HCV-induced human HCC cells.<xref rid="b38-ott-9-191" ref-type="bibr">38</xref> According to these results, GBP2 has been discussed as a possible control factor in tumor development.<xref rid="b44-ott-9-191" ref-type="bibr">44</xref> The validation analysis revealed that <italic>GBP1</italic> and <italic>GBP2</italic> were the DEGs in HCC samples. Thus, the increased expression ratio of <italic>GBP1</italic> and <italic>GBP2</italic> in JFH-1-infected HCC samples compared with the mock-infected ones revealed that <italic>GBP1</italic> and <italic>GBP2</italic> might be used as two possible control factors in HCC development.</p><p>As an enzyme belonging to the immunoglobulin superfamily, <italic>ICAM1</italic> plays an important role in innate and adaptive immune responses.<xref rid="b45-ott-9-191" ref-type="bibr">45</xref> Results of an enzyme-linked immunosorbent assay showed that the serum concentration of ICAM1 is significantly increased in patients with acute viral hepatitis and severe chronic active hepatitis C.<xref rid="b46-ott-9-191" ref-type="bibr">46</xref>,<xref rid="b47-ott-9-191" ref-type="bibr">47</xref> In chronic hepatitis C patients and patients with non-B, non-C chronic liver diseases, the serum levels of soluble ICAM-1 is a promising noninvasive marker of liver disease activity.<xref rid="b48-ott-9-191" ref-type="bibr">48</xref> Thus, <italic>ICAM1</italic> might be a candidate biomarker of JFH-1-infected HCC.</p><p>The forkhead protein FoxA1 (or hepatocyte nuclear factor 3&#x003b1;) is a TF and a major determinant of estrogen receptor (ER)-&#x003b1; activity.<xref rid="b49-ott-9-191" ref-type="bibr">49</xref> Estrogens can protect hepatocytes from malignancy, due to which men have a higher incidence of HCC than women.<xref rid="b50-ott-9-191" ref-type="bibr">50</xref> However, overexpression of ER&#x003b1; is related to the development of HCC.<xref rid="b51-ott-9-191" ref-type="bibr">51</xref> MiR-18a elevation that mediates ER&#x003b1; downregulation has been identified in females with HCC.<xref rid="b52-ott-9-191" ref-type="bibr">52</xref> Results from quantitative real-time PCR showed that elevated miR-20a levels are positively correlated with the severity of HCV-infected patients;<xref rid="b53-ott-9-191" ref-type="bibr">53</xref> thus, miR-20a may serve as a potential biomarker in HCV-mediated disease.<xref rid="b54-ott-9-191" ref-type="bibr">54</xref> In this study, <italic>Foxa1</italic> was relatively downregulated in JFH-1-infected samples and was targeted by miRNAs such as miR-20a, miR-17-5p, miR-106a, and miR-519d; meanwhile, miR-17 and miR-20a were DE-miRNAs in the HCC samples downloaded from TCGA. Therefore, these miRNAs might serve as potential biomarkers in HCV-mediated HCC.</p><p>The <italic>FDFT1</italic> gene functions as a key regulator in the cholesterol biosynthesis pathway.<xref rid="b55-ott-9-191" ref-type="bibr">55</xref>
<italic>FDFT1</italic> directs sterol biosynthesis to a branch resulting in the exclusive synthesis of cholesterol.<xref rid="b56-ott-9-191" ref-type="bibr">56</xref> This was inconsistent with the result of this study that <italic>FDFT1</italic> was enriched in the cholesterol biosynthesis process. Park et al<xref rid="b57-ott-9-191" ref-type="bibr">57</xref> revealed the critical role of <italic>FDFT1</italic> in HCV replication. They showed that siRNA-mediated silencing of <italic>FDFT1</italic> gene impairs HCV replication and YM53601-inhibited activity of FDFT1 enzyme abrogates HCV propagation, indicating that <italic>FDFT1</italic> is a host factor for HCV. They also observed that HCV infection elevated the level of FDFT1 protein rather than <italic>FDFT1</italic> mRNA,<xref rid="b57-ott-9-191" ref-type="bibr">57</xref> demonstrating that HCV might modulate FDFT1 protein level to facilitate its own propagation.</p><p>The <italic>MSMO1</italic> gene (also known as sterol-C4-methyl oxidase) was relatively downregulated in HCC samples. MSMO1 is reported to be involved in the biosynthetic and metabolic processes of sterol and cholesterol.<xref rid="b58-ott-9-191" ref-type="bibr">58</xref>,<xref rid="b59-ott-9-191" ref-type="bibr">59</xref> HCV infection is partly dependent on membrane cholesterol.<xref rid="b60-ott-9-191" ref-type="bibr">60</xref> In this study, <italic>MSMO1</italic> was continuously downregulated, demonstrating that sterol/cholesterol metabolism had been altered in HCV-infected cells. Glucose-6-phosphatase (G6PC) is a key enzyme catalyzing the final step of gluconeogenesis.<xref rid="b61-ott-9-191" ref-type="bibr">61</xref> The expression of G6PC is negatively correlated with the tumor grades.<xref rid="b62-ott-9-191" ref-type="bibr">62</xref>,<xref rid="b63-ott-9-191" ref-type="bibr">63</xref> Wang et al showed that elevation of miR-23a can severely suppress gluconeogenesis in HCC by downregulating its target gene <italic>G6PC</italic>.<xref rid="b63-ott-9-191" ref-type="bibr">63</xref> In this study, <italic>MSMO1</italic> was targeted by miR-23a and miR-23b, indicating that miR-23a and miR-23b might be the targets to alter gluconeogenesis, and sterol and cholesterol metabolic processes in HCC.</p><p>The <italic>MVD</italic> (EC 4.1.1.33) gene encodes a key enzyme in the mevalonate pathway, which catalyzes the metabolism of isoprenoids.<xref rid="b64-ott-9-191" ref-type="bibr">64</xref>,<xref rid="b65-ott-9-191" ref-type="bibr">65</xref> Isoprenoids participate in and are essential for diverse cellular functions, ranging from cholesterol synthesis to growth control.<xref rid="b65-ott-9-191" ref-type="bibr">65</xref> In this study, <italic>MVD</italic> was enriched in biological processes including cholesterol/sterol/steroid/isoprenoid metabolic/biosynthetic processes. All the isoprenoids were required for the HCV RNA replication or energy metabolism. These results indicated the vital role of <italic>MVD</italic> in HCV-related HCC.</p><p>Like <italic>MVD</italic>, <italic>HMGCS2</italic>, and <italic>DHCR7</italic>, genes were also enriched in biological processes such as cholesterol/sterol/steroid and/or isoprenoid metabolic/biosynthetic processes. HMGCS2 enzyme catalyzes the first step in isoprenoid biosynthesis, a site controlling the cholesterol pathway.<xref rid="b66-ott-9-191" ref-type="bibr">66</xref> DHCR7 enzyme catalyzes the last step in the biosynthesis of cholesterol.<xref rid="b67-ott-9-191" ref-type="bibr">67</xref> In our study, <italic>HMGCS2</italic> was not only a DEG in HCC samples downloaded from TCGA but also a co-regulated gene in cluster 3. Therefore, both <italic>HMGCS2</italic> and <italic>DHCR7</italic> were vital genetic factors regulating cholesterol metabolism to control the energy metabolism of HCV, thereby controlling the replication of HCV. However, there are no experimental studies that had verified the important roles of <italic>HMGCS2</italic> and <italic>DHCR7</italic>.</p></sec><sec><title>Conclusion</title><p>In conclusion, we identified the clusters of co-regulated genes with similar temporal expression patterns in the JFH-1-infected HCC samples compared with the mock-infected samples. <italic>IRF1</italic> and <italic>Foxa1</italic> were the targets of miR-130a, miR-17-5p, and miR-20a. <italic>PPARGC1A</italic> was the target of miR-29a, miR-29b, and miR-29c, and <italic>MSMO1</italic> was the target of miR-23a and miR-23b. Both the up and down co-regulated genes and miRNAs were related to HCV-induced human HCC. Therefore, they could be used as candidate biomarkers of JFH-1-infected HCC. However, further studies are still needed to testify the viability of the above-mentioned assumptions.</p></sec></body><back><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ott-9-191"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosetti</surname><given-names>C</given-names></name><name><surname>Turati</surname><given-names>F</given-names></name><name><surname>La Vecchia</surname><given-names>C</given-names></name></person-group><article-title>Hepatocellular carcinoma epidemiology</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2014</year><volume>28</volume><issue>5</issue><fpage>753</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">25260306</pub-id></element-citation></ref><ref id="b2-ott-9-191"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>RL</given-names></name><name><surname>Baack</surname><given-names>B</given-names></name><name><surname>Smith</surname><given-names>BD</given-names></name><name><surname>Yartel</surname><given-names>A</given-names></name><name><surname>Pitasi</surname><given-names>M</given-names></name><name><surname>Falck-Ytter</surname><given-names>Y</given-names></name></person-group><article-title>Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies</article-title><source>Ann Intern Med</source><year>2013</year><volume>158</volume><fpage>329</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">23460056</pub-id></element-citation></ref><ref id="b3-ott-9-191"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singal</surname><given-names>A</given-names></name><name><surname>Freeman</surname><given-names>D</given-names><suffix>Jr</suffix></name><name><surname>Anand</surname><given-names>B</given-names></name></person-group><article-title>Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma</article-title><source>Aliment Pharmacol Ther</source><year>2010</year><volume>32</volume><fpage>851</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">20659285</pub-id></element-citation></ref><ref id="b4-ott-9-191"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shalmani</surname><given-names>H</given-names></name><name><surname>Ranjbar</surname><given-names>M</given-names></name><name><surname>Alizadeh</surname><given-names>A</given-names></name></person-group><article-title>Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease</article-title><source>J Liver</source><year>2013</year><volume>3</volume><fpage>2167</fpage><lpage>2889</lpage></element-citation></ref><ref id="b5-ott-9-191"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalto</surname><given-names>G</given-names></name><name><surname>Cervello</surname><given-names>M</given-names></name><name><surname>Giannitrapani</surname><given-names>L</given-names></name><name><surname>Dantona</surname><given-names>F</given-names></name><name><surname>Terranova</surname><given-names>A</given-names></name><name><surname>Castagnetta</surname><given-names>LA</given-names></name></person-group><article-title>Epidemiology, risk factors, and natural history of hepatocellular carcinoma</article-title><source>Ann N Y Acad Sci</source><year>2002</year><volume>963</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">12095924</pub-id></element-citation></ref><ref id="b6-ott-9-191"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishioka</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>J</given-names></name><name><surname>Furuta</surname><given-names>S</given-names></name><etal/></person-group><article-title>A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan</article-title><source>Cancer</source><year>1991</year><volume>67</volume><fpage>429</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">1845946</pub-id></element-citation></ref><ref id="b7-ott-9-191"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asselah</surname><given-names>T</given-names></name><name><surname>Rubbia-Brandt</surname><given-names>L</given-names></name><name><surname>Marcellin</surname><given-names>P</given-names></name><name><surname>Negro</surname><given-names>F</given-names></name></person-group><article-title>Steatosis in chronic hepatitis C: why does it really matter?</article-title><source>Gut</source><year>2006</year><volume>55</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">16344578</pub-id></element-citation></ref><ref id="b8-ott-9-191"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poynard</surname><given-names>T</given-names></name><name><surname>Ratziu</surname><given-names>V</given-names></name><name><surname>McHutchison</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C</article-title><source>Hepatology</source><year>2003</year><volume>38</volume><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">12829989</pub-id></element-citation></ref><ref id="b9-ott-9-191"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanwal</surname><given-names>S</given-names></name><name><surname>Mahmood</surname><given-names>T</given-names></name></person-group><article-title>Hepatitis C virus resistance to interferon therapy: an alarming situation</article-title><source>Cent Eur J Biol</source><year>2014</year><volume>9</volume><fpage>1155</fpage><lpage>1167</lpage></element-citation></ref><ref id="b10-ott-9-191"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirasaki</surname><given-names>T</given-names></name><name><surname>Honda</surname><given-names>M</given-names></name><name><surname>Shimakami</surname><given-names>T</given-names></name><etal/></person-group><article-title>MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells</article-title><source>J Virol</source><year>2013</year><volume>87</volume><fpage>5270</fpage><lpage>5286</lpage><pub-id pub-id-type="pmid">23449803</pub-id></element-citation></ref><ref id="b11-ott-9-191"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowell</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Guyton</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis</article-title><source>Hepatol Int</source><year>2012</year><volume>6</volume><fpage>475</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">21735316</pub-id></element-citation></ref><ref id="b12-ott-9-191"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhanja Chowdhury</surname><given-names>J</given-names></name><name><surname>Shrivastava</surname><given-names>S</given-names></name><name><surname>Steele</surname><given-names>R</given-names></name><name><surname>Di Bisceglie</surname><given-names>AM</given-names></name><name><surname>Ray</surname><given-names>R</given-names></name><name><surname>Ray</surname><given-names>RB</given-names></name></person-group><article-title>Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating MIR-130a</article-title><source>J Virol</source><year>2012</year><volume>86</volume><fpage>10221</fpage><lpage>10225</lpage><pub-id pub-id-type="pmid">22787204</pub-id></element-citation></ref><ref id="b13-ott-9-191"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>W</given-names></name><name><surname>Tian</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Bonkovsky</surname><given-names>HL</given-names></name></person-group><article-title>MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins</article-title><source>Hepatology</source><year>2010</year><volume>51</volume><fpage>1494</fpage><lpage>1504</lpage><pub-id pub-id-type="pmid">20127796</pub-id></element-citation></ref><ref id="b14-ott-9-191"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>JC</given-names></name><name><surname>Yeh</surname><given-names>YJ</given-names></name><name><surname>Tseng</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Let-7b is a novel regulator of hepatitis C virus replication</article-title><source>Cell Mol Life Sci</source><year>2012</year><volume>69</volume><fpage>2621</fpage><lpage>2633</lpage><pub-id pub-id-type="pmid">22391672</pub-id></element-citation></ref><ref id="b15-ott-9-191"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name></person-group><article-title>Hcrp1, a novel gene that is down-regulated in hepatocellular carcinoma, encodes a growth-inhibitory protein</article-title><source>Biochem Biophys Res Commun</source><year>2003</year><volume>311</volume><fpage>1057</fpage><lpage>1066</lpage><pub-id pub-id-type="pmid">14623289</pub-id></element-citation></ref><ref id="b16-ott-9-191"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>J-Z</given-names></name><name><surname>Wang</surname><given-names>H-Y</given-names></name><name><surname>Chen</surname><given-names>Z-J</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>M-C</given-names></name></person-group><article-title>Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>4932</fpage><lpage>4943</lpage><pub-id pub-id-type="pmid">12118372</pub-id></element-citation></ref><ref id="b17-ott-9-191"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakita</surname><given-names>T</given-names></name><name><surname>Pietschmann</surname><given-names>T</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><etal/></person-group><article-title>Production of infectious hepatitis C virus in tissue culture from a cloned viral genome</article-title><source>Nat Med</source><year>2005</year><volume>11</volume><fpage>791</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">15951748</pub-id></element-citation></ref><ref id="b18-ott-9-191"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackham</surname><given-names>S</given-names></name><name><surname>Baillie</surname><given-names>A</given-names></name><name><surname>Al-Hababi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Gene expression profiling indicates the roles of host oxidative stress, apoptosis, lipid metabolism, and intracellular transport genes in the replication of hepatitis C virus</article-title><source>J Virol</source><year>2010</year><volume>84</volume><fpage>5404</fpage><lpage>5414</lpage><pub-id pub-id-type="pmid">20200238</pub-id></element-citation></ref><ref id="b19-ott-9-191"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautier</surname><given-names>L</given-names></name><name><surname>Cope</surname><given-names>L</given-names></name><name><surname>Bolstad</surname><given-names>BM</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name></person-group><article-title>Affy &#x02013; analysis of Affymetrix GeneChip data at the probe level</article-title><source>Bioinformatics</source><year>2004</year><volume>20</volume><fpage>307</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">14960456</pub-id></element-citation></ref><ref id="b20-ott-9-191"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Hobbs</surname><given-names>B</given-names></name><name><surname>Collin</surname><given-names>F</given-names></name><etal/></person-group><article-title>Exploration, normalization, and summaries of high density oligonucleotide array probe level data</article-title><source>Biostatistics</source><year>2003</year><volume>4</volume><fpage>249</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">12925520</pub-id></element-citation></ref><ref id="b21-ott-9-191"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>L</given-names></name><name><surname>Futschik</surname><given-names>ME</given-names></name></person-group><article-title>Mfuzz: a software package for soft clustering of microarray data</article-title><source>Bioinformation</source><year>2007</year><volume>2</volume><fpage>5</fpage><pub-id pub-id-type="pmid">18084642</pub-id></element-citation></ref><ref id="b22-ott-9-191"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Futschik</surname><given-names>ME</given-names></name><name><surname>Carlisle</surname><given-names>B</given-names></name></person-group><article-title>Noise-robust soft clustering of gene expression time-course data</article-title><source>J Bioinform Comput Biol</source><year>2005</year><volume>3</volume><fpage>965</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">16078370</pub-id></element-citation></ref><ref id="b23-ott-9-191"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>DW</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Tan</surname><given-names>Q</given-names></name><etal/></person-group><article-title>The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists</article-title><source>Genome Biol</source><year>2007</year><volume>8</volume><fpage>183</fpage></element-citation></ref><ref id="b24-ott-9-191"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>D</given-names></name></person-group><article-title>Status of the transcription factors database (TFD)</article-title><source>Nucleic Acids Res</source><year>1993</year><volume>21</volume><fpage>3117</fpage><lpage>3118</lpage><pub-id pub-id-type="pmid">8332533</pub-id></element-citation></ref><ref id="b25-ott-9-191"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J-S</given-names></name><name><surname>Hung</surname><given-names>W-S</given-names></name><name><surname>Chan</surname><given-names>H-H</given-names></name><name><surname>Tsai</surname><given-names>S-J</given-names></name><name><surname>Sun</surname><given-names>HS</given-names></name></person-group><article-title>In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma</article-title><source>Bioinformatics</source><year>2013</year><volume>29</volume><fpage>420</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">23267173</pub-id></element-citation></ref><ref id="b26-ott-9-191"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name></person-group><article-title>TSGene: a web resource for tumor suppressor genes</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><fpage>D970</fpage><lpage>D976</lpage><pub-id pub-id-type="pmid">23066107</pub-id></element-citation></ref><ref id="b27-ott-9-191"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franceschini</surname><given-names>A</given-names></name><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Frankild</surname><given-names>S</given-names></name><etal/></person-group><article-title>STRING v9. 1: protein-protein interaction networks, with increased coverage and integration</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><fpage>D808</fpage><lpage>D815</lpage><pub-id pub-id-type="pmid">23203871</pub-id></element-citation></ref><ref id="b28-ott-9-191"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Kirov</surname><given-names>S</given-names></name><name><surname>Snoddy</surname><given-names>J</given-names></name></person-group><article-title>WebGestalt: an integrated system for exploring gene sets in various biological contexts</article-title><source>Nucleic Acids Res</source><year>2005</year><volume>33</volume><fpage>W741</fpage><lpage>W748</lpage><pub-id pub-id-type="pmid">15980575</pub-id></element-citation></ref><ref id="b29-ott-9-191"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title><source>J R Stat Soc Series B</source><year>1995</year><volume>57</volume><fpage>289</fpage><lpage>300</lpage></element-citation></ref><ref id="b30-ott-9-191"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbloom</surname><given-names>KR</given-names></name><name><surname>Dreszer</surname><given-names>TR</given-names></name><name><surname>Pheasant</surname><given-names>M</given-names></name><etal/></person-group><article-title>Encode whole-genome data in the UCSC genome browser</article-title><source>Nucleic Acids Res</source><year>2010</year><volume>38</volume><fpage>D620</fpage><lpage>D625</lpage><pub-id pub-id-type="pmid">19920125</pub-id></element-citation></ref><ref id="b31-ott-9-191"><label>31</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kohl</surname><given-names>M</given-names></name><name><surname>Wiese</surname><given-names>S</given-names></name><name><surname>Warscheid</surname><given-names>B</given-names></name></person-group><article-title>Cytoscape: software for visualization and analysis of biological networks</article-title><person-group person-group-type="editor"><name><surname>Eisenacher</surname><given-names>M</given-names></name><name><surname>Hamacher</surname><given-names>M</given-names></name><name><surname>Stephan</surname><given-names>C</given-names></name></person-group><source>Data Mining in Proteomics</source><publisher-loc>Berlin</publisher-loc><publisher-name>Springer</publisher-name><year>2011</year><fpage>291</fpage><lpage>303</lpage></element-citation></ref><ref id="b32-ott-9-191"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekman</surname><given-names>D</given-names></name><name><surname>Light</surname><given-names>S</given-names></name><name><surname>Bj&#x000f6;rklund</surname><given-names>&#x000c5;K</given-names></name><name><surname>Elofsson</surname><given-names>A</given-names></name></person-group><article-title>What properties characterize the hub proteins of the protein-protein interaction network of <italic>Saccharomyces cerevisiae?</italic></article-title><source>Genome Biol</source><year>2006</year><volume>7</volume><fpage>R45</fpage><pub-id pub-id-type="pmid">16780599</pub-id></element-citation></ref><ref id="b33-ott-9-191"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bader</surname><given-names>GD</given-names></name><name><surname>Hogue</surname><given-names>CW</given-names></name></person-group><article-title>An automated method for finding molecular complexes in large protein interaction networks</article-title><source>BMC Bioinformatics</source><year>2003</year><volume>4</volume><fpage>2</fpage><pub-id pub-id-type="pmid">12525261</pub-id></element-citation></ref><ref id="b34-ott-9-191"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>Oshlack</surname><given-names>A</given-names></name></person-group><article-title>A scaling normalization method for differential expression analysis of RNA-seq data</article-title><source>Genome Biol</source><year>2010</year><volume>11</volume><fpage>R25</fpage><pub-id pub-id-type="pmid">20196867</pub-id></element-citation></ref><ref id="b35-ott-9-191"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>edgeR: a bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="b36-ott-9-191"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>S</given-names></name><name><surname>Harada</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>White</surname><given-names>R</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name></person-group><article-title>Assignment of the human interferon regulatory factor-1 (IRF1) gene to chromosome 5q23&#x02013;q31</article-title><source>Genomics</source><year>1991</year><volume>10</volume><fpage>1097</fpage><lpage>1099</lpage><pub-id pub-id-type="pmid">1680796</pub-id></element-citation></ref><ref id="b37-ott-9-191"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kajita</surname><given-names>A</given-names></name><name><surname>Morizane</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Interferon gamma enhances anti-viral activity induced by double-stranded RNA in keratinocytes</article-title><source>J Dermatol Sci</source><year>2013</year><volume>69</volume><fpage>e77</fpage><lpage>e78</lpage></element-citation></ref><ref id="b38-ott-9-191"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Du</surname><given-names>Q</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Interferon-gamma induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1)</article-title><source>Cancer Lett</source><year>2012</year><volume>314</volume><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">22056812</pub-id></element-citation></ref><ref id="b39-ott-9-191"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wietzke-Braun</surname><given-names>P</given-names></name><name><surname>Maouzi</surname><given-names>AB</given-names></name><name><surname>M&#x000e4;nhardt</surname><given-names>LB</given-names></name><name><surname>Bickeb&#x000f6;ller</surname><given-names>H</given-names></name><name><surname>Ramadori</surname><given-names>G</given-names></name><name><surname>Mihm</surname><given-names>S</given-names></name></person-group><article-title>Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection</article-title><source>Eur J Gastroenterol Hepatol</source><year>2006</year><volume>18</volume><fpage>991</fpage><lpage>997</lpage><pub-id pub-id-type="pmid">16894313</pub-id></element-citation></ref><ref id="b40-ott-9-191"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cloonan</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>MK</given-names></name><name><surname>Steptoe</surname><given-names>AL</given-names></name><etal/></person-group><article-title>The miR-17-5p microRNA is a key regulator of the g1/s phase cell cycle transition</article-title><source>Genome Biol</source><year>2008</year><volume>9</volume><fpage>R127</fpage><pub-id pub-id-type="pmid">18700987</pub-id></element-citation></ref><ref id="b41-ott-9-191"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Downregulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1</article-title><source>Cell Death Dis</source><year>2010</year><volume>1</volume><fpage>e94</fpage><pub-id pub-id-type="pmid">21368870</pub-id></element-citation></ref><ref id="b42-ott-9-191"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsauer</surname><given-names>K</given-names></name><name><surname>Farlik</surname><given-names>M</given-names></name><name><surname>Zupkovitz</surname><given-names>G</given-names></name><etal/></person-group><article-title>Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-&#x003b3;-inducible gbp2 gene</article-title><source>Proc Natl Acad Sci U S A</source><year>2007</year><volume>104</volume><fpage>2849</fpage><pub-id pub-id-type="pmid">17293456</pub-id></element-citation></ref><ref id="b43-ott-9-191"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traver</surname><given-names>MK</given-names></name><name><surname>Henry</surname><given-names>SC</given-names></name><name><surname>Cantillana</surname><given-names>V</given-names></name><etal/></person-group><article-title>Immunity-related GTPase M (IRGM) proteins influence the localization of guanylate-binding protein 2 (GBP2) by modulating macroautophagy</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>30471</fpage><lpage>30480</lpage><pub-id pub-id-type="pmid">21757726</pub-id></element-citation></ref><ref id="b44-ott-9-191"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godoy</surname><given-names>P</given-names></name><name><surname>Cadenas</surname><given-names>C</given-names></name><name><surname>Hellwig</surname><given-names>B</given-names></name><etal/></person-group><article-title>Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response</article-title><source>Breast Cancer</source><year>2014</year><volume>21</volume><fpage>491</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">23001506</pub-id></element-citation></ref><ref id="b45-ott-9-191"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawson</surname><given-names>C</given-names></name><name><surname>Wolf</surname><given-names>S</given-names></name></person-group><article-title>Icam-1 signaling in endothelial cells</article-title><source>Pharmacol Rep</source><year>2009</year><volume>61</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">19307690</pub-id></element-citation></ref><ref id="b46-ott-9-191"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nouri-Aria</surname><given-names>K</given-names></name><name><surname>Koskinas</surname><given-names>J</given-names></name><name><surname>Tibbs</surname><given-names>C</given-names></name><name><surname>Portmann</surname><given-names>B</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name></person-group><article-title>Serum intercellular adhesion molecule-1 levels in chronic hepatitis C: association with disease activity and response to interferon alpha</article-title><source>Gut</source><year>1995</year><volume>36</volume><fpage>599</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">7737571</pub-id></element-citation></ref><ref id="b47-ott-9-191"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Z&#x000f6;hrens</surname><given-names>G</given-names></name><name><surname>Armbrust</surname><given-names>T</given-names></name><name><surname>Pirzer</surname><given-names>U</given-names></name><name><surname>Meyer zum B&#x000fc;schenfelde</surname><given-names>KH</given-names></name><name><surname>Ramadori</surname><given-names>G</given-names></name></person-group><article-title>Intercellular adhesion molecule-1 concentration in sera of patients with acute and chronic liver disease: relationship to disease activity and cirrhosis</article-title><source>Hepatology</source><year>1993</year><volume>18</volume><fpage>798</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">8104856</pub-id></element-citation></ref><ref id="b48-ott-9-191"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Gohary</surname><given-names>AM</given-names></name><name><surname>Fawaz</surname><given-names>NA</given-names></name><name><surname>Hassoba</surname><given-names>HM</given-names></name><name><surname>Serwah</surname><given-names>A</given-names></name><name><surname>Ali</surname><given-names>M</given-names></name></person-group><article-title>Soluble ICAM-1 in patients with chronic hepatitis C infection: a prognostic marker of disease activity</article-title><source>Egypt J Immunol</source><year>2003</year><volume>11</volume><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">16734123</pub-id></element-citation></ref><ref id="b49-ott-9-191"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurtado</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>KA</given-names></name><name><surname>Ross-Innes</surname><given-names>CS</given-names></name><name><surname>Schmidt</surname><given-names>D</given-names></name><name><surname>Carroll</surname><given-names>JS</given-names></name></person-group><article-title>FOXA1 is a key determinant of estrogen receptor function and endocrine response</article-title><source>Nat Genet</source><year>2011</year><volume>43</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">21151129</pub-id></element-citation></ref><ref id="b50-ott-9-191"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>WH</given-names></name><name><surname>Yeh</surname><given-names>SH</given-names></name><name><surname>Lu</surname><given-names>CC</given-names></name><etal/></person-group><article-title>MicroRNA-18a prevents estrogen receptor-&#x003b1; expression, promoting proliferation of hepatocellular carcinoma cells</article-title><source>Gastroenterology</source><year>2009</year><volume>136</volume><fpage>683</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">19027010</pub-id></element-citation></ref><ref id="b51-ott-9-191"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Deng</surname><given-names>G</given-names></name><etal/></person-group><article-title>Estrogen receptor &#x003b1; polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><fpage>2001</fpage><lpage>2009</lpage><pub-id pub-id-type="pmid">16762623</pub-id></element-citation></ref><ref id="b52-ott-9-191"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CL</given-names></name><name><surname>Yeh</surname><given-names>KH</given-names></name><name><surname>Liu</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor-&#x003b1; in female hepatocellular carcinoma</article-title><source>Int J Cancer</source><year>2015</year><volume>136</volume><fpage>761</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">24975878</pub-id></element-citation></ref><ref id="b53-ott-9-191"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrivastava</surname><given-names>S</given-names></name><name><surname>Petrone</surname><given-names>J</given-names></name><name><surname>Steele</surname><given-names>R</given-names></name><etal/></person-group><article-title>Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression</article-title><source>Hepatology</source><year>2013</year><volume>58</volume><fpage>863</fpage><lpage>871</lpage><pub-id pub-id-type="pmid">23390075</pub-id></element-citation></ref><ref id="b54-ott-9-191"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrivastava</surname><given-names>S</given-names></name><name><surname>Mukherjee</surname><given-names>A</given-names></name><name><surname>Ray</surname><given-names>RB</given-names></name></person-group><article-title>Hepatitis C virus infection, microrna and liver disease progression</article-title><source>World J Hepatol</source><year>2013</year><volume>5</volume><fpage>479</fpage><pub-id pub-id-type="pmid">24073299</pub-id></element-citation></ref><ref id="b55-ott-9-191"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Sawashita</surname><given-names>J</given-names></name><name><surname>Higuchi</surname><given-names>K</given-names></name></person-group><article-title>Functional polymorphisms of the Lss and Fdft1 genes in laboratory rats</article-title><source>Exp Anim</source><year>2007</year><volume>56</volume><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">17460354</pub-id></element-citation></ref><ref id="b56-ott-9-191"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tansey</surname><given-names>TR</given-names></name><name><surname>Shechter</surname><given-names>I</given-names></name></person-group><article-title>Structure and regulation of mammalian squalene synthase</article-title><source>Biochim Biophys Acta</source><year>2000</year><volume>1529</volume><fpage>49</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">11111077</pub-id></element-citation></ref><ref id="b57-ott-9-191"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>E-M</given-names></name><name><surname>Nguyen</surname><given-names>LN</given-names></name><name><surname>Lim</surname><given-names>Y-S</given-names></name><name><surname>Hwang</surname><given-names>SB</given-names></name></person-group><article-title>Farnesyl-diphosphate farnesyltransferase 1 regulates hepatitis C virus propagation</article-title><source>FEBS Lett</source><year>2014</year><volume>588</volume><fpage>1813</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">24690320</pub-id></element-citation></ref><ref id="b58-ott-9-191"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyck</surname><given-names>MK</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Tsoi</surname><given-names>S</given-names></name><name><surname>Grant</surname><given-names>J</given-names></name><name><surname>Dixon</surname><given-names>WT</given-names></name><name><surname>Foxcroft</surname><given-names>GR</given-names></name></person-group><article-title>Reproductive technologies and the porcine embryonic transcriptome</article-title><source>Anim Reprod Sci</source><year>2014</year><volume>149</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">24953007</pub-id></element-citation></ref><ref id="b59-ott-9-191"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukushima</surname><given-names>R</given-names></name><name><surname>Kaneto</surname><given-names>M</given-names></name><name><surname>Kitagawa</surname><given-names>H</given-names></name></person-group><article-title>Microarray analysis of leflunomide-induced limb malformations in CD-1 mice</article-title><source>Reprod Toxicol</source><year>2010</year><volume>29</volume><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">19751817</pub-id></element-citation></ref><ref id="b60-ott-9-191"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapadia</surname><given-names>SB</given-names></name><name><surname>Barth</surname><given-names>H</given-names></name><name><surname>Baumert</surname><given-names>T</given-names></name><name><surname>McKeating</surname><given-names>JA</given-names></name><name><surname>Chisari</surname><given-names>FV</given-names></name></person-group><article-title>Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I</article-title><source>J Virol</source><year>2007</year><volume>81</volume><fpage>374</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">17050612</pub-id></element-citation></ref><ref id="b61-ott-9-191"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Cong</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><etal/></person-group><article-title>Maternal low-protein diet induces gender-dependent changes in epigenetic regulation of the glucose-6-phosphatase gene in newborn piglet liver</article-title><source>J Nutr</source><year>2012</year><volume>142</volume><fpage>1659</fpage><lpage>1665</lpage><pub-id pub-id-type="pmid">22833655</pub-id></element-citation></ref><ref id="b62-ott-9-191"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bensinger</surname><given-names>SJ</given-names></name><name><surname>Christofk</surname><given-names>HR</given-names></name></person-group><article-title>New aspects of the Warburg effect in cancer cell biology</article-title><source>Semin Cell Dev Biol</source><year>2012</year><volume>23</volume><fpage>352</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">22406683</pub-id></element-citation></ref><ref id="b63-ott-9-191"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Hsu</surname><given-names>SH</given-names></name><name><surname>Frankel</surname><given-names>W</given-names></name><name><surname>Ghoshal</surname><given-names>K</given-names></name><name><surname>Jacob</surname><given-names>ST</given-names></name></person-group><article-title>Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha</article-title><source>Hepatology</source><year>2012</year><volume>56</volume><fpage>186</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">22318941</pub-id></element-citation></ref><ref id="b64-ott-9-191"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Molecular cloning, characterization, and function analysis of a mevalonate pyrophosphate decarboxylase gene from <italic>Ganoderma lucidum</italic></article-title><source>Mol Biol Rep</source><year>2012</year><volume>39</volume><fpage>6149</fpage><lpage>6159</lpage><pub-id pub-id-type="pmid">22203490</pub-id></element-citation></ref><ref id="b65-ott-9-191"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name></person-group><article-title>Regulation of the mevalonate pathway</article-title><source>Nature</source><year>1990</year><volume>343</volume><fpage>425</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">1967820</pub-id></element-citation></ref><ref id="b66-ott-9-191"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenspan</surname><given-names>MD</given-names></name><name><surname>Yudkovitz</surname><given-names>JB</given-names></name><name><surname>Lo</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Inhibition of hydroxymethylglutaryl-coenzyme a synthase by l&#x02013;659,699</article-title><source>Proc Natl Acad Sci U S A</source><year>1987</year><volume>84</volume><fpage>7488</fpage><lpage>7492</lpage><pub-id pub-id-type="pmid">2890166</pub-id></element-citation></ref><ref id="b67-ott-9-191"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witsch-Baumgartner</surname><given-names>M</given-names></name><name><surname>Ciara</surname><given-names>E</given-names></name><name><surname>L&#x000f6;ffler</surname><given-names>J</given-names></name><etal/></person-group><article-title>Frequency gradients of DHCR7 mutations in patients with Smith-Lemli-Opitz syndrome in Europe: evidence for different origins of common mutations</article-title><source>Eur J Hum Genet</source><year>2001</year><volume>9</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">11175299</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ott-9-191" position="float"><label>Figure 1</label><caption><p>Soft cluster analysis of the temporal expression profiles of co-regulated genes.</p><p><bold>Note:</bold> Membership values were color encoded with red denoting high membership values and green denoting low membership values.</p></caption><graphic xlink:href="ott-9-191Fig1"/></fig><fig id="f2-ott-9-191" position="float"><label>Figure 2</label><caption><p>The combination of the protein-to-protein interaction network, miRNA regulatory network, and transcriptional regulatory network of the up co-regulated (<bold>A</bold>) and down co-regulated genes (<bold>B</bold>).</p><p><bold>Notes:</bold> Gene, miRNA, and TF are represented by nodes. Circles indicate genes, triangles indicate transcription factors, and quadrangles indicate miRNA. Lines between nodes indicate the interrelationships.</p><p><bold>Abbreviations:</bold> miRNA, microRNA; TF, transcription factor.</p></caption><graphic xlink:href="ott-9-191Fig2"/></fig><fig id="f3-ott-9-191" position="float"><label>Figure 3</label><caption><p>The most significant modules of the networks of the up co-regulated (<bold>A</bold>) and down co-regulated genes (<bold>B</bold>).</p><p><bold>Notes:</bold> Genes are represented by nodes. Circles indicate genes, triangles indicate transcription factors, and quadrangles indicate miRNAs. Lines between nodes indicate the interrelationships.</p></caption><graphic xlink:href="ott-9-191Fig3"/></fig><fig id="f4-ott-9-191" position="float"><label>Figure 4</label><caption><p>Network of the most hub nodes in the combined network of up co-regulated (<bold>A</bold>) and down co-regulated genes (<bold>B</bold>).</p><p><bold>Notes:</bold> Gene and TF are represented by nodes. Circles indicate genes and triangles indicate transcription factors. Lines between nodes indicate the interrelationships.</p><p><bold>Abbreviation:</bold> TF, transcription factor.</p></caption><graphic xlink:href="ott-9-191Fig4"/></fig><table-wrap id="t1-ott-9-191" position="float"><label>Table 1</label><caption><p>The enriched top ten GO functional terms for DEGs in JFH-1-infected Huh7 cell samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Genes</th><th valign="top" align="left" rowspan="1" colspan="1">Terms</th><th valign="top" align="left" rowspan="1" colspan="1">Description</th><th valign="top" align="left" rowspan="1" colspan="1">Count</th><th valign="top" align="left" rowspan="1" colspan="1">Gene symbols</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="10" valign="top" align="left" colspan="1">Up co-regulated</td><td valign="top" align="left" rowspan="1" colspan="1">GO:0048705</td><td valign="top" align="left" rowspan="1" colspan="1">Skeletal system morphogenesis</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>PTHLH, HOXA2, TBX15, HOXB7, HOXA5, BMPR1B</italic></td><td valign="top" align="left" rowspan="1" colspan="1">3.67E-03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0030182</td><td valign="top" align="left" rowspan="1" colspan="1">Neuron differentiation</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>KLF7, HOXA2, MCOLN3, CD44, CXCR4, ATL1, NTN4, PTPRR, RORA, BMPR1B, TGFB2</italic></td><td valign="top" align="left" rowspan="1" colspan="1">6.99E-03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0009891</td><td valign="top" align="left" rowspan="1" colspan="1">Positive regulation of biosynthetic process</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>ICAM1, KLF7, FHL2, RORA, PPARGC1A, TCF7L1, TGFB2, PTHLH, MURC, HOXA2, NPM2, IRF1, TFAP2B, TGFB1I1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.12E-02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0051173</td><td valign="top" align="left" rowspan="1" colspan="1">Positive regulation of nitrogen compound metabolic process</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>ICAM1, KLF7, FHL2, RORA, PPARGC1A, TCF7L1, PTHLH, MURC, HOXA2, NPM2, IRF1, TFAP2B, TGFB1I1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.51E-02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0048704</td><td valign="top" align="left" rowspan="1" colspan="1">Embryonic skeletal system morphogenesis</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HOXA2, TBX15, HOXB7, HOXA5</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.54E-02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0031328</td><td valign="top" align="left" rowspan="1" colspan="1">Positive regulation of cellular biosynthetic process</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>ICAM1, KLF7, FHL2, RORA, PPARGC1A, TCF7L1, PTHLH, MURC, HOXA2, NPM2, IRF1, TFAP2B, TGFB1I1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">2.32E-02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0048858</td><td valign="top" align="left" rowspan="1" colspan="1">Cell projection morphogenesis</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>KLF7, HOXA2, BBS7, CXCR4, ATL1, BMPR1B, BBS10</italic></td><td valign="top" align="left" rowspan="1" colspan="1">2.75E-02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0001501</td><td valign="top" align="left" rowspan="1" colspan="1">Skeletal system development</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>PTHLH, HOXA2, TBX15, HOXB7, TUFT1, HOXA5, FHL2, BMPR1B</italic></td><td valign="top" align="left" rowspan="1" colspan="1">2.81E-02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0045935</td><td valign="top" align="left" rowspan="1" colspan="1">Positive regulation of nucleobase, nucleoside, nucleotide, and nucleic acid metabolic process</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>PTHLH, MURC, KLF7, HOXA2, NPM2, TFAP2B, IRF1, FHL2, TGFB1I1, RORA, PPARGC1A, TCF7L1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">3.11E-02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0032990</td><td valign="top" align="left" rowspan="1" colspan="1">Cell part morphogenesis</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>KLF7, HOXA2, BBS7, CXCR4, ATL1, BMPR1B, BBS10</italic></td><td valign="top" align="left" rowspan="1" colspan="1">3.13E-02</td></tr><tr><td rowspan="10" valign="top" align="left" colspan="1">Down co-regulated</td><td valign="top" align="left" rowspan="1" colspan="1">GO:0008202</td><td valign="top" align="left" rowspan="1" colspan="1">Steroid metabolic process</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>TM7SF2, ACOX2, TNFSF4, MVD, FDFT1, CYP39A1, HMGCS2, PRLR, DHCR7, AKR1B10, HSD11B2, CAT, NR1H4</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.21E-06</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0006694</td><td valign="top" align="left" rowspan="1" colspan="1">Steroid biosynthetic process</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>TM7SF2, CYP39A1, PRLR, HMGCS2, MVD, DHCR7, HSD11B2, FDFT1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">2.76E-05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0008203</td><td valign="top" align="left" rowspan="1" colspan="1">Cholesterol metabolic process</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>TM7SF2, CYP39A1, TNFSF4, HMGCS2, MVD, DHCR7, CAT, FDFT1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">4.61E-05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0016125</td><td valign="top" align="left" rowspan="1" colspan="1">Sterol metabolic process</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>TM7SF2, CYP39A1, TNFSF4, HMGCS2, MVD, DHCR7, CAT, FDFT1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">8.37E-05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0006695</td><td valign="top" align="left" rowspan="1" colspan="1">Cholesterol biosynthetic process</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>TM7SF2, HMGCS2, MVD, DHCR7, FDFT1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.38E-04</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0045859</td><td valign="top" align="left" rowspan="1" colspan="1">Regulation of protein kinase activity</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>SPRY1, KISS1R, PRLR, HEXIM2, RGS3, CDKN2C, DGKK, LRP8, PKIB, CDKN3, DUSP6</italic></td><td valign="top" align="left" rowspan="1" colspan="1">3.13E-03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0043549</td><td valign="top" align="left" rowspan="1" colspan="1">Regulation of kinase activity</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>SPRY1, KISS1R, PRLR, HEXIM2, RGS3, CDKN2C, DGKK, LRP8, PKIB, CDKN3, DUSP6</italic></td><td valign="top" align="left" rowspan="1" colspan="1">3.99E-03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0051338</td><td valign="top" align="left" rowspan="1" colspan="1">Regulation of transferase activity</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>SPRY1, KISS1R, PRLR, HEXIM2, RGS3, CDKN2C, DGKK, LRP8, PKIB, CDKN3, DUSP6</italic></td><td valign="top" align="left" rowspan="1" colspan="1">5.31E-03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0042325</td><td valign="top" align="left" rowspan="1" colspan="1">Regulation of phosphorylation</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>SPRY1, KISS1R, PRLR, HEXIM2, RGS3, CDKN2C, SMAD6, DGKK, LRP8, PKIB, CDKN3, DUSP6</italic></td><td valign="top" align="left" rowspan="1" colspan="1">9.07E-03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0006720</td><td valign="top" align="left" rowspan="1" colspan="1">Isoprenoid metabolic process</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HMGCS2, MVD, RBP2, FDFT1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.05E-02</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ott-9-191"><p><bold>Abbreviations:</bold> GO, gene ontology; DEGs, differentially expressed genes.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ott-9-191" position="float"><label>Table 2</label><caption><p>The enriched pathways for DEGs in JFH-1-infected Huh7 cell samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Genes</th><th valign="top" align="left" rowspan="1" colspan="1">Terms</th><th valign="top" align="left" rowspan="1" colspan="1">Description</th><th valign="top" align="left" rowspan="1" colspan="1">Count</th><th valign="top" align="left" rowspan="1" colspan="1">Gene symbols</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Up co-regulated</td><td valign="top" align="left" rowspan="1" colspan="1">hsa00500</td><td valign="top" align="left" rowspan="1" colspan="1">Starch and sucrose metabolism</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>MGAM, UGT2B4, PGM2L1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">5.48E-02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Down co-regulated</td><td valign="top" align="left" rowspan="1" colspan="1">hsa00100</td><td valign="top" align="left" rowspan="1" colspan="1">Steroid biosynthesis</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>TM7SF2, DHCR7, FDFT1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">2.05E-02</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-ott-9-191"><p><bold>Abbreviation:</bold> DEGs, differentially expressed genes.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ott-9-191" position="float"><label>Table 3</label><caption><p>TFs, oncogenes, and TSGs among the co-regulated genes of JFH-1-infected samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Genes</th><th valign="top" align="left" rowspan="1" colspan="1">TFs</th><th valign="top" align="left" rowspan="1" colspan="1">TSGs</th><th valign="top" align="left" rowspan="1" colspan="1">Oncogene</th><th valign="top" align="left" rowspan="1" colspan="1">Other</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Up co-regulated</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>BACH2, FOSL2, IRF1, KLF11, KLF7, MAFK, HOXA2, HOXA5, HOXB7, RORA, TFAP2B, TGFB1I1</italic></td><td valign="top" align="left" rowspan="1" colspan="1"><italic>ADPRH, BACH2, IRF1, L3MBTL4, POU6F2, PPP3CC, RASSF2, WNT11, BHLHE41, FABP3, TRIM3</italic></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>PTHLH, TGFB2, CD44, FHL2</italic></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Down co-regulated</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>FOXA1, HLF, ID1, ID3, NR4A2, POU2AF1, CDX2, NR1H4, NR2F2, SMAD6</italic></td><td valign="top" align="left" rowspan="1" colspan="1"><italic>DUSP6, FRK, RBM14, CDKN2C, DKK1, EXTL2, RASSF10</italic></td><td valign="top" align="left" rowspan="1" colspan="1"><italic>ETV1, GPX2</italic></td><td valign="top" align="left" rowspan="1" colspan="1"><italic>FRAT1, NR4A2, CDX2</italic></td></tr></tbody></table><table-wrap-foot><fn id="tfn3-ott-9-191"><p><bold>Abbreviations:</bold> TFs, transcription factors; TSGs, tumor suppressor genes.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-ott-9-191" position="float"><label>Table 4</label><caption><p>The degree of top 25 genes in the PPI network of the co-regulated genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" valign="top" align="left" rowspan="1">Up co-regulated
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Down co-regulated
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Symbol</th><th valign="top" align="left" rowspan="1" colspan="1">Degree</th><th valign="top" align="left" rowspan="1" colspan="1">Symbol</th><th valign="top" align="left" rowspan="1" colspan="1">Degree</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">IRF1</td><td valign="top" align="left" rowspan="1" colspan="1">25</td><td valign="top" align="left" rowspan="1" colspan="1">FOXA1</td><td valign="top" align="left" rowspan="1" colspan="1">49</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PTHLH</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">ACSL4</td><td valign="top" align="left" rowspan="1" colspan="1">15</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BHLHE41</td><td valign="top" align="left" rowspan="1" colspan="1">23</td><td valign="top" align="left" rowspan="1" colspan="1">ATP2B2</td><td valign="top" align="left" rowspan="1" colspan="1">14</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BACH2</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">CAT</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TRIM3</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">SLC4A4</td><td valign="top" align="left" rowspan="1" colspan="1">11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACSL1</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">CDX2</td><td valign="top" align="left" rowspan="1" colspan="1">10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MAFK</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">RHOC</td><td valign="top" align="left" rowspan="1" colspan="1">10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CNR1</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">MSMO1</td><td valign="top" align="left" rowspan="1" colspan="1">8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NEGR1</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">CLDN2</td><td valign="top" align="left" rowspan="1" colspan="1">7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PGM2L1</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">HMGCS2</td><td valign="top" align="left" rowspan="1" colspan="1">7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ICAM1</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">FDFT1</td><td valign="top" align="left" rowspan="1" colspan="1">7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IRF9</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">DHCR7</td><td valign="top" align="left" rowspan="1" colspan="1">7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MX1</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">MVD</td><td valign="top" align="left" rowspan="1" colspan="1">6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD44</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">CA2</td><td valign="top" align="left" rowspan="1" colspan="1">5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD8A</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">AKR1B10</td><td valign="top" align="left" rowspan="1" colspan="1">5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GBP1</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">CCNB1</td><td valign="top" align="left" rowspan="1" colspan="1">5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GBP2</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">CCNF</td><td valign="top" align="left" rowspan="1" colspan="1">5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">INHBB</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">CYP39A1</td><td valign="top" align="left" rowspan="1" colspan="1">5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">REEP1</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">ENTPD5</td><td valign="top" align="left" rowspan="1" colspan="1">4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HOXA5</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">PLAU</td><td valign="top" align="left" rowspan="1" colspan="1">4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KIF21B</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">SORD</td><td valign="top" align="left" rowspan="1" colspan="1">4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RAB6B</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">CDKN2C</td><td valign="top" align="left" rowspan="1" colspan="1">4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PPARGC1A</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">NT5E</td><td valign="top" align="left" rowspan="1" colspan="1">4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CXCR4</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">TM7SF2</td><td valign="top" align="left" rowspan="1" colspan="1">4</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-ott-9-191"><p><bold>Abbreviation:</bold> PPI, protein&#x02013;protein interaction.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-ott-9-191" position="float"><label>Table 5</label><caption><p>The enriched top five GO functional terms and pathways for co-regulated genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Genes</th><th valign="top" align="left" rowspan="1" colspan="1">Term</th><th valign="top" align="left" rowspan="1" colspan="1">Description</th><th valign="top" align="left" rowspan="1" colspan="1">Count</th><th valign="top" align="left" rowspan="1" colspan="1">Gene symbol</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="2" valign="top" align="left" colspan="1">Up co-regulated</td><td valign="top" align="left" rowspan="1" colspan="1">GO:0006955</td><td valign="top" align="left" rowspan="1" colspan="1">Immune response</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>ICAM1, GBP2, GBP1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">3.40E-02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0009615</td><td valign="top" align="left" rowspan="1" colspan="1">Response to virus</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>IRF9, MX1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">4.74E-02</td></tr><tr><td rowspan="13" valign="top" align="left" colspan="1">Down co-regulated</td><td valign="top" align="left" rowspan="1" colspan="1">GO:0006694</td><td valign="top" align="left" rowspan="1" colspan="1">Steroid biosynthetic process</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>CYP39A1, HMGCS2, MVD, DHCR7</italic></td><td valign="top" align="left" rowspan="1" colspan="1">9.53E-07</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0008203</td><td valign="top" align="left" rowspan="1" colspan="1">Cholesterol metabolic process</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>CYP39A1, HMGCS2, MVD, DHCR7</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.21E-06</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0016125</td><td valign="top" align="left" rowspan="1" colspan="1">Sterol metabolic process</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>CYP39A1, HMGCS2, MVD, DHCR7</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.61E-06</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0008202</td><td valign="top" align="left" rowspan="1" colspan="1">Steroid metabolic process</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>CYP39A1, HMGCS2, MVD, DHCR7</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.30E-05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0006695</td><td valign="top" align="left" rowspan="1" colspan="1">Cholesterol biosynthetic process</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HMGCS2, MVD, DHCR7</italic></td><td valign="top" align="left" rowspan="1" colspan="1">2.13E-05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0016126</td><td valign="top" align="left" rowspan="1" colspan="1">Sterol biosynthetic process</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HMGCS2, MVD, DHCR7</italic></td><td valign="top" align="left" rowspan="1" colspan="1">3.89E-05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0008610</td><td valign="top" align="left" rowspan="1" colspan="1">Lipid biosynthetic process</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>CYP39A1, HMGCS2, MVD, DHCR7</italic></td><td valign="top" align="left" rowspan="1" colspan="1">5.30E-05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0008299</td><td valign="top" align="left" rowspan="1" colspan="1">Isoprenoid biosynthetic process</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HMGCS2, MVD</italic></td><td valign="top" align="left" rowspan="1" colspan="1">5.90E-03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0006720</td><td valign="top" align="left" rowspan="1" colspan="1">Isoprenoid metabolic process</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HMGCS2, MVD</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.29E-02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0030324</td><td valign="top" align="left" rowspan="1" colspan="1">Lung development</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>DHCR7, FOXA1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">2.90E-02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0030323</td><td valign="top" align="left" rowspan="1" colspan="1">Respiratory tube development</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>DHCR7, FOXA1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">2.98E-02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO:0060541</td><td valign="top" align="left" rowspan="1" colspan="1">Respiratory system development</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>DHCR7, FOXA1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">3.16E-02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">hsa00900</td><td valign="top" align="left" rowspan="1" colspan="1">Terpenoid backbone biosynthesis</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>HMGCS2, MVD</italic></td><td valign="top" align="left" rowspan="1" colspan="1">8.83E-03</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-ott-9-191"><p><bold>Abbreviation:</bold> GO, gene ontology.</p></fn></table-wrap-foot></table-wrap></floats-group></article>